International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 210-216
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Assessment of Plasma Endostatin Levels in Patients with Acute Myeloblastic and Lymphoblastic Leukemia
Simten DAGDAS1, Gulsum OZET1, Mesude YILMAZ1, Murat ALBAYRAK1, Funda CERAN1
Ankara Numune Training and Research Hospital, Department of Hematology, Ankara, TURKEY
Keywords: Acute myeloblastic leukemia, Acute lymphoblastic leukemia, Angiogenesis, Endostatin
In this study, we evaluated the plasma levels of endostatin (PE) and its prognostic importance in patients with acute myeloblastic (AML) and lypmhoblastic leukemia (ALL). We therefore analyzed plasma levels of endostatin before the chemotherapy and during the complete remission period in adult ALL and AML patients. The PE levels of the control group were significantly lower than both cases with ALL and AML. The patients with AML during remission had significantly higher PE levels than the levels at initial diagnosis. No statistically significant difference was detected in patients with ALL. In addition, the survival rates of the cases with ALL whose PE levels are higher than 2.5 ng/ml, are significantly lower. Our results suggest that the elevated plasma levels of endostatin during the remission in patients with AML imply the intensity of angiogenesis inhibition during the remission. Furthermore our findings in ALL patients suggest that endostatin levels may predict the overall survival of these patients.
Simten DAGDAS1, Gulsum OZET1, Mesude YILMAZ1, Murat ALBAYRAK1, Funda CERAN1
Ankara Numune Training and Research Hospital, Department of Hematology, Ankara, TURKEY
Keywords: Acute myeloblastic leukemia, Acute lymphoblastic leukemia, Angiogenesis, Endostatin
In this study, we evaluated the plasma levels of endostatin (PE) and its prognostic importance in patients with acute myeloblastic (AML) and lypmhoblastic leukemia (ALL). We therefore analyzed plasma levels of endostatin before the chemotherapy and during the complete remission period in adult ALL and AML patients. The PE levels of the control group were significantly lower than both cases with ALL and AML. The patients with AML during remission had significantly higher PE levels than the levels at initial diagnosis. No statistically significant difference was detected in patients with ALL. In addition, the survival rates of the cases with ALL whose PE levels are higher than 2.5 ng/ml, are significantly lower. Our results suggest that the elevated plasma levels of endostatin during the remission in patients with AML imply the intensity of angiogenesis inhibition during the remission. Furthermore our findings in ALL patients suggest that endostatin levels may predict the overall survival of these patients.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |